Provided by Tiger Trade Technology Pte. Ltd.

Halozyme Therapeutics

107.11
+0.11000.10%
Volume:377.45K
Turnover:40.48M
Market Cap:12.16B
PE:31.67
High:108.17
Open:107.96
Low:106.34
Close:107.00
52wk High:111.15
52wk Low:61.23
Shares:113.50M
Float Shares:112.00M
Volume Ratio:0.32
T/O Rate:0.34%
Dividend:- -
Dividend Rate:- -
EPS(TTM):3.38
EPS(LYR):2.56
ROE:173.67%
ROA:25.49%
PB:84.69
PE(LYR):41.84

Loading ...

Stock Track | Halozyme Therapeutics Soars 7.71% Intraday on Strong Q1 Earnings Beat and Analyst Optimism

Stock Track
·
May 12

Morgan Stanley Cuts Price Target on Halozyme Therapeutics to $93 From $96, Keeps Overweight Rating

MT Newswires Live
·
May 12

Analysts’ Top Healthcare Picks: Halozyme (HALO), MindWalk Holdings (HYFT)

TIPRANKS
·
May 12

Halozyme (HALO) Gets a Buy from H.C. Wainwright

TIPRANKS
·
May 12

Stock Track | Halozyme Therapeutics Soars 6.91% in Pre-Market on Q1 Earnings Beat

Stock Track
·
May 12

Financial Education Initiative: Huaxia Fund's 'Financial Reading Companion' Series Explores Commodity Price Trends and HALO Trading Strategy

Deep News
·
May 12

Halozyme Therapeutics Shares Rise in Extended Trade Following Results, Last up 3.4% at $68.68

THOMSON REUTERS
·
May 12

Halozyme beats Q1 revenue estimates, sets $1 billion buyback

Reuters
·
May 12

GUIDANCE:(HALO) Halozyme Therapeutics Expects Full Year 2026 Adjusted EPS Range $7.75 - $8.25, vs. FactSet Est of $8.06

MT Newswires Live
·
May 12

Earnings Flash (HALO) Halozyme Therapeutics Posts Q1 Revenue $376.7M, vs. FactSet Est of $358.6M

MT Newswires Live
·
May 12

Earnings Flash (HALO) Halozyme Therapeutics Posts Q1 Adjusted EPS $1.60, vs. FactSet Est of $1.55

MT Newswires Live
·
May 12

Halozyme Q1 2026 net income rises 27.06% to $150 million; revenue climbs 42% to $377 million

Reuters
·
May 12

BRIEF-Halozyme Therapeutics Q1 Adjusted EPS USD 1.6 Vs. IBES Estimate USD 1.53

Reuters
·
May 12

Halozyme Therapeutics Inc - Announces $1 Bln Share Repurchase Program, to Buy Back at Least $400 Mln in 2026

THOMSON REUTERS
·
May 12

Halozyme Therapeutics Q1 Adjusted EPS USD 1.6 VS. Ibes Estimate USD 1.53

THOMSON REUTERS
·
May 12

Halozyme Therapeutics Q1 Revenue USD 376.708 Million VS. Ibes Estimate USD 359.1 Million

THOMSON REUTERS
·
May 12

U.S. Earnings Preview: After Market Close May 11

Dow Jones
·
May 12

Halozyme Therapeutics Inc expected to post earnings of $1.53 a share - Earnings Preview

Reuters
·
May 09

Halozyme shareholders approve Ernst & Young as 2026 auditor at annual meeting

Reuters
·
May 08

Halozyme announces global collaboration and license agreement with GSK

TIPRANKS
·
May 08